Sébastian Wittnebel

High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry

Nicolas Mounier, Carmen Canals, Christian Gisselbrecht et al. · Biology of Blood and Marrow Transplantation · 2011 · 117 citations · Full text

Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD

Adèle de Masson, Jean‐David Bouaziz, Régis Peffault de Latour et al. · Blood · 2012 · 45 citations

The Decreased Susceptibility of Bcr/Abl Targets to NK Cell-Mediated Lysis in Response to Imatinib Mesylate Involves Modulation of NKG2D Ligands, GM1 Expression, and Synapse Formation

Christelle Cebo, Sylvie Da Rocha, Sébastian Wittnebel et al. · The Journal of Immunology · 2006 · 41 citations · Full text

Mutations of the von Hippel–Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma

Aurélie Perier, Giulia Fregni, Sébastian Wittnebel et al. · Oncogene · 2011 · 30 citations

Genitourinary Cancer, Kidney Research, Renal Pathology +7

A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study

Frédèric Selle, Sébastian Wittnebel, Pierre Biron et al. · Annals of Oncology · 2014 · 30 citations · Full text

Urology, Phase Ii Trial, Cisplatin-based Chemotherapy +8